JP2024514202A - Ｅｒｋ１／２の複素環式阻害剤の使用 - Google Patents
Ｅｒｋ１／２の複素環式阻害剤の使用 Download PDFInfo
- Publication number
- JP2024514202A JP2024514202A JP2023563209A JP2023563209A JP2024514202A JP 2024514202 A JP2024514202 A JP 2024514202A JP 2023563209 A JP2023563209 A JP 2023563209A JP 2023563209 A JP2023563209 A JP 2023563209A JP 2024514202 A JP2024514202 A JP 2024514202A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- administered
- acceptable salt
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 23
- 102000019149 MAP kinase activity proteins Human genes 0.000 title abstract description 11
- 108040008097 MAP kinase activity proteins Proteins 0.000 title abstract description 11
- 125000000623 heterocyclic group Chemical group 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 335
- 201000011510 cancer Diseases 0.000 claims abstract description 238
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 86
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 86
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 45
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 45
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 38
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 37
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 37
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 37
- 201000001441 melanoma Diseases 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims description 437
- 229940125904 compound 1 Drugs 0.000 claims description 313
- 150000003839 salts Chemical class 0.000 claims description 304
- 238000011282 treatment Methods 0.000 claims description 82
- 102000043136 MAP kinase family Human genes 0.000 claims description 58
- 108091054455 MAP kinase family Proteins 0.000 claims description 58
- 230000037361 pathway Effects 0.000 claims description 41
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 24
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 24
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 24
- 201000004101 esophageal cancer Diseases 0.000 claims description 24
- 206010033128 Ovarian cancer Diseases 0.000 claims description 23
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 23
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 23
- 208000021780 appendiceal neoplasm Diseases 0.000 claims description 23
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 23
- 206010017758 gastric cancer Diseases 0.000 claims description 23
- 201000010536 head and neck cancer Diseases 0.000 claims description 23
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 23
- 201000011549 stomach cancer Diseases 0.000 claims description 23
- 206010046766 uterine cancer Diseases 0.000 claims description 23
- 230000035772 mutation Effects 0.000 claims description 22
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 19
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims description 19
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 19
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 17
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 claims description 17
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 17
- 239000012824 ERK inhibitor Substances 0.000 claims description 16
- 102100029974 GTPase HRas Human genes 0.000 claims description 16
- 102100039788 GTPase NRas Human genes 0.000 claims description 16
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims description 16
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 16
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 16
- 229940124785 KRAS inhibitor Drugs 0.000 claims description 15
- 229940124647 MEK inhibitor Drugs 0.000 claims description 15
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 claims description 15
- 230000002074 deregulated effect Effects 0.000 claims description 15
- 102000016914 ras Proteins Human genes 0.000 claims description 15
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 11
- 230000003213 activating effect Effects 0.000 claims description 7
- 102200006538 rs121913530 Human genes 0.000 claims description 7
- 102100030708 GTPase KRas Human genes 0.000 claims description 5
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 5
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical class [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims description 4
- 206010004593 Bile duct cancer Diseases 0.000 claims description 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims 2
- 206010024291 Leukaemias acute myeloid Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- PWHIUQBBGPGFFV-GOSISDBHSA-N N-[(1S)-2-amino-1-(3-chloro-5-fluorophenyl)ethyl]-1-[5-methyl-2-(oxan-4-ylamino)pyrimidin-4-yl]imidazole-4-carboxamide Chemical group NC[C@H](C1=CC(=CC(=C1)F)Cl)NC(=O)C=1N=CN(C=1)C1=NC(=NC=C1C)NC1CCOCC1 PWHIUQBBGPGFFV-GOSISDBHSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 55
- 201000010099 disease Diseases 0.000 description 43
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 26
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 23
- 239000000203 mixture Substances 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 12
- 235000012054 meals Nutrition 0.000 description 11
- 238000009097 single-agent therapy Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000001394 metastastic effect Effects 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 231100000682 maximum tolerated dose Toxicity 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 229940126560 MAPK inhibitor Drugs 0.000 description 3
- 208000037844 advanced solid tumor Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000037843 metastatic solid tumor Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 230000005723 MEK inhibition Effects 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000004262 breast ductal adenoma Diseases 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006650 fundamental cellular process Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000025444 tumor of salivary gland Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163176131P | 2021-04-16 | 2021-04-16 | |
| US63/176,131 | 2021-04-16 | ||
| PCT/US2022/024841 WO2022221547A1 (en) | 2021-04-16 | 2022-04-14 | Uses of heterocyclic inhibitors of erk1/2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2024514202A true JP2024514202A (ja) | 2024-03-28 |
Family
ID=83640772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563209A Pending JP2024514202A (ja) | 2021-04-16 | 2022-04-14 | Ｅｒｋ１／２の複素環式阻害剤の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240207269A1 (de) |
| EP (1) | EP4322956A1 (de) |
| JP (1) | JP2024514202A (de) |
| KR (1) | KR20240026893A (de) |
| CN (1) | CN117500502A (de) |
| AU (1) | AU2022257020A1 (de) |
| CA (1) | CA3215387A1 (de) |
| TW (1) | TW202308633A (de) |
| WO (1) | WO2022221547A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017026159A2 (pt) | 2015-06-15 | 2018-08-14 | Asana Biosciences, Llc | inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017026159A2 (pt) * | 2015-06-15 | 2018-08-14 | Asana Biosciences, Llc | inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer |
| JP2019518063A (ja) * | 2016-06-20 | 2019-06-27 | クラ オンコロジー， インコーポレイテッド | Ｅｒｋ阻害剤を用いた扁平上皮細胞癌の処置 |
| WO2020046966A1 (en) * | 2018-08-27 | 2020-03-05 | Kura Oncology, Inc. | Treatment of adenocarcinomas with mapk pathway inhibitors |
-
2022
- 2022-04-14 WO PCT/US2022/024841 patent/WO2022221547A1/en active Application Filing
- 2022-04-14 CN CN202280042727.9A patent/CN117500502A/zh active Pending
- 2022-04-14 CA CA3215387A patent/CA3215387A1/en active Pending
- 2022-04-14 EP EP22788945.8A patent/EP4322956A1/de active Pending
- 2022-04-14 US US18/555,071 patent/US20240207269A1/en active Pending
- 2022-04-14 KR KR1020237039424A patent/KR20240026893A/ko unknown
- 2022-04-14 TW TW111114340A patent/TW202308633A/zh unknown
- 2022-04-14 AU AU2022257020A patent/AU2022257020A1/en active Pending
- 2022-04-14 JP JP2023563209A patent/JP2024514202A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022221547A1 (en) | 2022-10-20 |
| KR20240026893A (ko) | 2024-02-29 |
| CA3215387A1 (en) | 2022-10-20 |
| CN117500502A (zh) | 2024-02-02 |
| EP4322956A1 (de) | 2024-02-21 |
| AU2022257020A1 (en) | 2023-11-30 |
| TW202308633A (zh) | 2023-03-01 |
| US20240207269A1 (en) | 2024-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2607944C2 (ru) | Синергические композиции ингибиторов pi3k и мек | |
| CN110494166A (zh) | 组合疗法 | |
| TW202122082A (zh) | 治療胃腸道基質瘤方法 | |
| CN114615982A (zh) | 用于治疗胃肠道间质瘤的瑞普替尼 | |
| TW201625243A (zh) | 用於治療黑素瘤之藥物組合 | |
| KR20240049796A (ko) | Erk1/2 및 kras g12c 억제제 조합 요법 | |
| TW202317124A (zh) | Erk1/2及shp2抑制劑之組合療法 | |
| JP2024514202A (ja) | Ｅｒｋ１／２の複素環式阻害剤の使用 | |
| US20140142128A1 (en) | Methods of treating a disease or disorder associated with bruton's tyrosine kinase | |
| US20180280370A1 (en) | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor | |
| CN117858725A (zh) | Erk1/2和egfr抑制剂组合疗法 | |
| KR20240055721A (ko) | Erk1/2 억제제 조합 요법 | |
| CN117940132A (zh) | Erk1/2和kras g12c抑制剂组合疗法 | |
| CN117897158A (zh) | Erk1/2和shp2抑制剂组合疗法 | |
| TW202317123A (zh) | Erk1/2及cdk4/6抑制劑之組合療法 | |
| KR20240096444A (ko) | Erk1/2 및 shp2 억제제 조합 요법 | |
| KR20240044419A (ko) | Erk1/2 및 egfr 억제제 조합 요법 | |
| WO2023187037A1 (en) | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer | |
| WO2024055039A1 (en) | Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240206 |